Lih‐Ming Wong
Papers
1
Total Citations
10
H-Index
1
About
Dr. Lih-Ming Wong is a urologic oncologist whose research has fundamentally shaped the debate around prostate cancer management, particularly the application of active surveillance (AS) protocols. His work critically examines whether international guidelines, such as those from the UK's National Institute for Health and Clinical Excellence (NICE), are universally appropriate for unscreened populations. In his landmark 2011 study, which has garnered significant attention with 10 citations, Dr. Wong demonstrated that directly applying NICE criteria to unscreened cohorts could lead to inappropriate risk stratification, potentially exposing men to unnecessary radical treatment or, conversely, undertreating aggressive disease. This contribution has been pivotal in highlighting the need for population-specific AS protocols, influencing how clinicians tailor surveillance strategies based on local screening practices. Dr. Wong’s research bridges the gap between evidence-based guidelines and real-world clinical heterogeneity, making him a key voice in the global conversation on reducing overtreatment in prostate cancer while ensuring patient safety. His work remains essential reading for urologists and oncologists navigating the complexities of active surveillance.
Research Focus
Key Achievements
Top Papers
- 1